SK281948B6 - Použitie trofoblastického beta-i-glykoproteínu - Google Patents
Použitie trofoblastického beta-i-glykoproteínu Download PDFInfo
- Publication number
- SK281948B6 SK281948B6 SK1187-96A SK118796A SK281948B6 SK 281948 B6 SK281948 B6 SK 281948B6 SK 118796 A SK118796 A SK 118796A SK 281948 B6 SK281948 B6 SK 281948B6
- Authority
- SK
- Slovakia
- Prior art keywords
- tbg
- glycoprotein
- autoimmune diseases
- blood
- treatment
- Prior art date
Links
- 102000007502 Pregnancy-Specific beta 1-Glycoproteins Human genes 0.000 title abstract 2
- 108010085648 Pregnancy-Specific beta 1-Glycoproteins Proteins 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 238000001990 intravenous administration Methods 0.000 claims abstract description 3
- 230000001573 trophoblastic effect Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 13
- 201000006417 multiple sclerosis Diseases 0.000 abstract description 8
- 230000036039 immunity Effects 0.000 abstract description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 5
- 230000002519 immonomodulatory effect Effects 0.000 abstract description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000005714 functional activity Effects 0.000 description 3
- 230000003169 placental effect Effects 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000001715 anti-suppressor Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000008407 joint function Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000001885 phytohemagglutinin Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010009346 Clonus Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU9494008169A RU2056852C1 (ru) | 1994-03-18 | 1994-03-18 | Средство для лечения аутоиммунных заболеваний с иммунодефицитом супрессоров и способ лечения аутоиммунных заболеваний |
| PCT/RU1995/000047 WO1995025531A1 (fr) | 1994-03-18 | 1995-03-16 | Agent therapeutique contre les maladies auto-immunes et mode de traitement |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK118796A3 SK118796A3 (en) | 1997-06-04 |
| SK281948B6 true SK281948B6 (sk) | 2001-09-11 |
Family
ID=20153349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1187-96A SK281948B6 (sk) | 1994-03-18 | 1995-03-16 | Použitie trofoblastického beta-i-glykoproteínu |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6150326A (zh) |
| EP (1) | EP0790059B1 (zh) |
| JP (1) | JPH09510473A (zh) |
| KR (1) | KR100382252B1 (zh) |
| CN (1) | CN1146156A (zh) |
| AT (1) | ATE260111T1 (zh) |
| AU (1) | AU699896B2 (zh) |
| BG (1) | BG62759B1 (zh) |
| CA (1) | CA2185892A1 (zh) |
| CZ (1) | CZ285856B6 (zh) |
| DE (2) | DE790059T1 (zh) |
| ES (1) | ES2107980T1 (zh) |
| FI (1) | FI963671A (zh) |
| GE (1) | GEP20012377B (zh) |
| GR (1) | GR980300023T1 (zh) |
| HU (1) | HUT75720A (zh) |
| NO (1) | NO963911L (zh) |
| PL (1) | PL179765B1 (zh) |
| RU (1) | RU2056852C1 (zh) |
| SK (1) | SK281948B6 (zh) |
| UA (1) | UA26939C2 (zh) |
| WO (1) | WO1995025531A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0030729D0 (en) * | 2000-12-16 | 2001-01-31 | Univ Nottingham | Substituted-4-Quinolones |
| AU2003282550C1 (en) * | 2002-10-09 | 2008-09-25 | Tolerx, Inc. | Molecules preferentially associated with effector T cells or regulatory T cells and methods of their use |
| RU2303995C1 (ru) * | 2006-04-28 | 2007-08-10 | Халлар Абдумуслимович Алиханов | Средство, обладающее иммунорегуляторным свойством и его применение для лечения аутоиммунных заболеваний |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1107772B (it) * | 1977-08-22 | 1985-11-25 | Cancer Res Inst Royal | Procedimento per la produzione di complessi macromolecolari prodotto ottenuto e composizioni farmaceutiche che lo contengono come ingrediente attivo |
| JPS61186322A (ja) * | 1985-02-13 | 1986-08-20 | Nippon Univ | 免疾調節剤 |
| IT1188646B (it) * | 1986-04-09 | 1988-01-20 | Ellem Ind Farmaceutica | Tripeptide ad attivita' immunostimolante |
| US4803072A (en) * | 1986-09-10 | 1989-02-07 | Smithkline Beckman Corporation | Immunomodulation |
| FR2609632B1 (fr) * | 1987-01-21 | 1991-03-29 | Shelly Marc | Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage |
| US5169835A (en) * | 1989-01-18 | 1992-12-08 | Oklahoma Medical Research Foundation | Pregancy specific proteins applications |
| FR2650183A1 (fr) * | 1989-07-25 | 1991-02-01 | Pasteur Institut | Proteines immunostimulantes, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et application de ces produits a des fins therapeutiques et de diagnostic |
| US5118669A (en) * | 1989-09-20 | 1992-06-02 | Hitachi Chemical Co., Ltd. | Peptides and intermediates therefor useful as antiallergic agents, vasodilators and immunoregulators |
| US5559097A (en) * | 1990-01-12 | 1996-09-24 | Idaho Research Foundation, Inc. | Use of a pregnancy specific protein as an immunosuppressive |
| RU1836957C (ru) * | 1990-03-25 | 1993-08-30 | 2-й Московский государственный медицинский институт им.Н.И.Пирогова | Способ получени трофобластического бета @ -гликопротеина |
| GB2251186A (en) * | 1990-12-04 | 1992-07-01 | Randall Neal Gatz | Polypeptide for use in treatment of autoimmune disease |
-
1994
- 1994-03-18 RU RU9494008169A patent/RU2056852C1/ru not_active IP Right Cessation
-
1995
- 1995-03-16 AT AT95913445T patent/ATE260111T1/de not_active IP Right Cessation
- 1995-03-16 CN CN95192635A patent/CN1146156A/zh active Pending
- 1995-03-16 AU AU20874/95A patent/AU699896B2/en not_active Ceased
- 1995-03-16 US US08/716,139 patent/US6150326A/en not_active Expired - Fee Related
- 1995-03-16 UA UA96093436A patent/UA26939C2/uk unknown
- 1995-03-16 HU HU9602558A patent/HUT75720A/hu unknown
- 1995-03-16 EP EP95913445A patent/EP0790059B1/en not_active Expired - Lifetime
- 1995-03-16 JP JP7524566A patent/JPH09510473A/ja not_active Ceased
- 1995-03-16 CA CA002185892A patent/CA2185892A1/en not_active Abandoned
- 1995-03-16 PL PL95316311A patent/PL179765B1/pl unknown
- 1995-03-16 WO PCT/RU1995/000047 patent/WO1995025531A1/ru active IP Right Grant
- 1995-03-16 SK SK1187-96A patent/SK281948B6/sk unknown
- 1995-03-16 DE DE0790059T patent/DE790059T1/de active Pending
- 1995-03-16 CZ CZ962747A patent/CZ285856B6/cs not_active IP Right Cessation
- 1995-03-16 KR KR1019960705237A patent/KR100382252B1/ko not_active IP Right Cessation
- 1995-03-16 DE DE69532611T patent/DE69532611D1/de not_active Expired - Lifetime
- 1995-03-16 GE GEAP19953411A patent/GEP20012377B/en unknown
- 1995-03-16 ES ES95913445T patent/ES2107980T1/es active Pending
-
1996
- 1996-09-17 FI FI963671A patent/FI963671A/fi not_active IP Right Cessation
- 1996-09-18 NO NO963911A patent/NO963911L/no not_active Application Discontinuation
- 1996-10-18 BG BG100921A patent/BG62759B1/bg unknown
-
1998
- 1998-04-30 GR GR980300023T patent/GR980300023T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPH09510473A (ja) | 1997-10-21 |
| EP0790059A1 (en) | 1997-08-20 |
| DE69532611D1 (de) | 2004-04-01 |
| EP0790059B1 (en) | 2004-02-25 |
| ATE260111T1 (de) | 2004-03-15 |
| FI963671A (fi) | 1996-11-14 |
| SK118796A3 (en) | 1997-06-04 |
| CN1146156A (zh) | 1997-03-26 |
| DE790059T1 (de) | 1998-03-12 |
| CZ285856B6 (cs) | 1999-11-17 |
| CZ274796A3 (en) | 1997-06-11 |
| EP0790059A4 (en) | 2000-11-02 |
| GR980300023T1 (en) | 1998-04-30 |
| UA26939C2 (uk) | 1999-12-29 |
| BG100921A (en) | 1997-12-30 |
| FI963671A0 (fi) | 1996-09-17 |
| US6150326A (en) | 2000-11-21 |
| GEP20012377B (en) | 2001-03-25 |
| KR970701557A (ko) | 1997-04-12 |
| AU699896B2 (en) | 1998-12-17 |
| NO963911D0 (no) | 1996-09-18 |
| NO963911L (no) | 1996-11-08 |
| PL316311A1 (en) | 1997-01-06 |
| KR100382252B1 (ko) | 2003-07-07 |
| AU2087495A (en) | 1995-10-09 |
| HU9602558D0 (en) | 1996-11-28 |
| RU2056852C1 (ru) | 1996-03-27 |
| CA2185892A1 (en) | 1995-09-28 |
| PL179765B1 (pl) | 2000-10-31 |
| HUT75720A (en) | 1997-05-28 |
| ES2107980T1 (es) | 1997-12-16 |
| WO1995025531A1 (fr) | 1995-09-28 |
| BG62759B1 (bg) | 2000-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ellie et al. | Neuropathy associated with “benign” anti-myelin-associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases | |
| Chaudhry et al. | Multifocal motor neuropathy: response to human immune globulin | |
| MXPA05012965A (es) | Uso de inhibidores de miostatina (gdf8) en conjuncion con corticoesteroides para el tratamiento de desordenes neuromusculares y composiciones farmaceuticas para ello. | |
| Murphy et al. | Encephalopathy following measles infection in children with chronic illness | |
| US20230099852A1 (en) | Treatment of autoimmune disease | |
| Robberecht et al. | Myasthenic syndrome caused by direct effect of chloroquine on neuromuscular junction | |
| Hirohata et al. | Elevation of cerebrospinal fluid interleukin-6 activity in patients with vasculitides and central nervous system involvement | |
| Miescher et al. | Combined steroid-cyclosporin treatment of chronic autoimmune diseases: clinical results and assessment of nephrotoxicity by renal biopsy | |
| Reckziegel et al. | Carbamazepine effects on Na+ currents in human dentate granule cells from epileptogenic tissue | |
| SK281948B6 (sk) | Použitie trofoblastického beta-i-glykoproteínu | |
| Alstergren et al. | Insufficient endogenous control of tumor necrosis factor-alpha contributes to temporomandibular joint pain and tissue destruction in rheumatoid arthritis. | |
| Bansil et al. | Serum soluble interleukin‐2 receptor levels in chronic progressive, stable and steroid‐treated multiple sclerosis | |
| Zuckner et al. | Evaluation of intra-articular thio-tepa in rheumatoid arthritis. | |
| Hassan et al. | The immunological consequences of gold therapy: a prospective study in patients with rheumatoid arthritis. | |
| Fung et al. | Is Sydenham's chorea an antiphospholipid syndrome? | |
| KR20190063211A (ko) | 골수 흡인 농축물-혈소판 농축혈장 복합체로 구성된 건병증 예방 또는 치료용 약학적 조성물 | |
| Rayfield et al. | Human fetal lymphocytes require T cell growth factors for cytotoxic responses. | |
| Axton, JHM & Garnett | Trial of oral oxamniquine in the treatment of schistosoma infection in children | |
| Manto et al. | Acute posterior multifocal placoid pigment epitheliopathy presenting as an aseptic meningitis | |
| Guenther et al. | Experiences with immunoglobulin-G infusions in the treatment of acute multiple sclerosis | |
| Adams | Studies in Diseases of the Blood, Vitamin B12 and Related Topics | |
| van der Hilst | Hyper IgD syndrome and type AA amyloidosis. | |
| Barnes | Use of the protamine titration and antiheparin compounds in certain hemorrhagic conditions | |
| CN106727582A (zh) | 自身免疫疾病的治疗 | |
| Wahezi et al. | Chapter Management Diseases of Childhood of the Connective Tissue |